Evidence map›Paper›PMID 42527031›Full record

ArticleJournal for immunotherapy of cancer2026

CXCR2-mediated metabolic interaction between prostate cancer cells and the immunosuppressive tumor microenvironment.

Yi Sun, Jun Jing, Shangqing Ren, Xu Luo, Wei Wen, Xin Jin, Guohua Zeng, Xuewen Jiang, Mo Zhang, Ju Guo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yi Sun *Urology, Guangzhou Medical University, Guangzhou, Guangdong, China.ORCID http://orcid.org/0000-0001-8688-4879
Jun Jing *Department of Rheumatology and Clinical Immunology, Shenshan Medical Center, Sun Yat-Sen Memorial Hospital, Shanwei, Guangdong, China.
Shangqing Ren *Robotic Minimally Invasive Surgery Center, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Xu LuoDepartment of Urology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China.
Wei WenDepartment of Urology, West China Tianfu Hospital, Sichuan University, Chengdu, Sichuan, China.
Xin JinDepartment of Urology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Guohua ZengGuangzhou Medical University, Guangzhou, Guangdong, China.
Xuewen JiangDepartment of Urology, Qilu Hospital of Shandong University, Jinan, Shandong, China ndyfy02371@ncu.edu.cn peterzhang623@gmail.com xwjiang@sdu.edu.cn.
Mo ZhangDepartment of Urology, The First Hospital of China Medical University, Shenyang, Liaoning, China ndyfy02371@ncu.edu.cn peterzhang623@gmail.com xwjiang@sdu.edu.cn.
Ju GuoDepartment of Urology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China ndyfy02371@ncu.edu.cn peterzhang623@gmail.com xwjiang@sdu.edu.cn.ORCID http://orcid.org/0009-0008-0881-0936

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeuroendocrine prostate cancer (NEPC) is characterized by strong immune evasion and profound metabolic reprogramming. A high regulatory T cell (Treg)/CD8

methodsTo investigate these mechanisms, prostate cancer cell lines and patient samples were analyzed using immunohistochemistry, flow cytometry, PCR, western blotting, and mass spectrometry. The interleukin (IL)-8/CXCR2 signaling pathway was targeted for intervention in two tumor-bearing mouse models.

resultsData revealed that IL-8/CXCR2 signaling drives the accumulation of free fatty acids and very-long-chain polyunsaturated fatty acids, leading to ferroptosis in tumor-infiltrating CD8

conclusionsThese findings highlight CXCR2 as a promising immunotherapeutic target for NEPC and underscore its relevance in translational medicine.

Indexed as

Prostatic NeoplasmsReceptors, Interleukin-8BTumor MicroenvironmentAnimalsCell Line, TumorHumansLymphocytes, Tumor-InfiltratingMaleMetabolic ReprogrammingMiceSignal TransductionT-Lymphocytes, RegulatoryTumor-Associated MacrophagesCXCR2 protein, humanReceptors, Interleukin-8BProstate CancerT cellT regulatory cell - TregTumor infiltrating lymphocyte - TIL

Identifiers

PMID42527031
PMCPMC13422945

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.